📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-09-07 14:45
477 analysed today
FollowTelegram
477
Today
149,878
All-time analysed
42,959
Positive
6,669
Negative
91,543
Neutral
8,639
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
6 announcements match the current filters (relevance ≥ 5).
Q1 FY27 Net Loss Narrows to ₹2.48 Cr; Revenue Up 27.4% YoY to ₹6.98 Cr
Krebs Biochemicals reported a 27.4% YoY increase in revenue from operations to ₹6.98 Cr (₹698.35 lacs) for Q1 ended June 30, 2026, compared to ₹5.48 Cr in Q1 FY26. Net loss narrowed significantly to ₹2.48 Cr from ₹5.32 Cr in the corresponding prior-year quarter. The company continues to face operational headwinds as its Vizag unit remains closed under an Andhra Pradesh Pollution Control Board order dated February 7, 2025. Additionally, the Board had previously approved the amalgamation of the company into Ipca Laboratories Limited (appointed date April 1, 2026), which remains subject to regulatory approvals.
Confidence: HIGH
What changedQ1 FY27 operational results showed higher revenue and reduced net losses YoY, while plant closure and amalgamation proceedings continue.
Why it mattersThe company has a deeply negative net worth (-₹162 Cr) and persistent net losses; progress on the proposed amalgamation with parent promoter Ipca Laboratories is the primary driver of future equity value.
Revenue from Operations: ₹6.98 CrNet Loss: ₹2.48 CrTotal Expenses: ₹9.62 CrBasic EPS: ₹-1.15
📅 Short termFinancial performance continues to reflect constrained operations with negative net profit, though cost controls helped narrow losses YoY.
📈 Long termLong-term outlook is fundamentally tied to the pending merger with Ipca Laboratories and resolution of environmental compliance at the Vizag unit.
⚠ Risk flags
- Ongoing closure of the Vizag manufacturing unit by APPCB
- Negative net worth and persistent net losses
- Regulatory approval risks for the proposed amalgamation with Ipca Laboratories
Key Highlights
Revenue from operations increased 27.4% YoY to ₹6.98 Cr (₹698.35 lacs) in Q1 FY27 vs ₹5.48 Cr in Q1 FY26
Net loss narrowed to ₹2.48 Cr (₹248.48 lacs) compared to a loss of ₹5.32 Cr in Q1 FY26
Total expenses stood at ₹9.62 Cr (₹962.48 lacs), reduced from ₹10.82 Cr in Q1 FY26
Operations at the Vizag manufacturing unit remain shut following an APPCB closure order dated February 7, 2025
Scheme of amalgamation with Ipca Laboratories Ltd (approved June 26, 2026) is pending necessary regulatory consents
👀 What to Watch
Track progress on the revocation of the APPCB closure order for the Vizag facility and monitor the statutory and shareholder approval milestones for the amalgamation with Ipca Laboratories.
KREBSBIO Board approves Q1 FY27 results; company faces Rs 225 Cr debt and negative net worth
Krebs Biochemicals and Industries Limited has approved its unaudited financial results for the quarter ended June 30, 2026. The company remains in a precarious financial position with a negative net worth of Rs 162 Cr and total debt of Rs 225 Cr. Historically, the company has struggled with profitability, reporting a net margin of -62.1% in FY25 and a net loss of Rs 26.92 Cr. Investors should monitor the full results for any signs of a turnaround through new product additions and promoter financial support.
Confidence: HIGH
What changedThe company has completed its board review and approved the financial performance data for the first quarter of the 2026-27 fiscal year.
Why it mattersGiven the company's negative net worth and high debt, quarterly results are critical indicators of whether the business can sustain operations or if further promoter infusion is required.
Quarter ended: June 30, 2026Debt: Rs 225 CrNet worth: Rs -162 CrPromoter holding: 72.7%FY25 Net Margin: -62.1%
📅 Short termThe stock may remain volatile as investors digest the specific revenue and loss figures from the Q1 filing.
📈 Long termThe long-term outlook is limited by material uncertainty regarding the company's ability to continue as a going concern unless it achieves a structural turnaround.
⚠ Risk flags
- Going concern uncertainty
- Negative net worth
- High debt-to-equity ratio
- Historical net losses
Key Highlights
Board meeting concluded at 01:30 p.m. on August 6, 2026, to approve Q1 results.
Company reported a negative net worth of INR 146.24 Cr as of March 31, 2025.
Total debt stands at Rs 225 Cr, significantly impacting the balance sheet stability.
Promoter holding is maintained at 72.7%, providing some assurance of continued support.
Net loss in FY25 widened by 36.5% to INR 26.92 Cr compared to the previous year.
👀 What to Watch
Review the full financial statement to check for any improvement in operating profit margins and whether the auditors have continued the 'Going Concern' qualification.
Krebs Biochemicals to Merge with Ipca Laboratories; Share Swap Ratio Set at 7:200
Krebs Biochemicals & Industries Limited has approved a Scheme of Amalgamation to merge with Ipca Laboratories Limited. Under the proposed scheme, Krebs shareholders will receive 7 equity shares of Ipca Laboratories (Re. 1 each) for every 200 equity shares of Krebs (Rs. 10 each). The merger aims to integrate Krebs' specialized fermentation-based API manufacturing capabilities into Ipca's larger operations to secure supply chains and optimize costs. The appointed date for the merger is April 1, 2026, subject to regulatory and shareholder approvals.
Key Highlights
Share swap ratio fixed at 7 shares of Ipca Laboratories for every 200 shares held in Krebs Biochemicals.
Ipca Laboratories reported a standalone total income of ₹7,431 Crores for FY26, while Krebs reported ₹26 Crores.
The merger will provide Ipca with unique fermentation-based API manufacturing facilities that it currently lacks.
Krebs is currently loss-making and will benefit from Ipca's financial strength and R&D capabilities.
The appointed date for the scheme is April 1, 2026, and it remains subject to SEBI and NCLT approvals.
👀 What to Watch
Investors should evaluate the merger based on the current market price of Ipca Laboratories to determine if the 7:200 swap ratio offers a premium over Krebs' current stock price. The merger provides Krebs shareholders an exit into a much larger, diversified, and profitable pharmaceutical entity.
Krebs Biochemicals to Merge with Ipca Laboratories; Share Swap Ratio Set at 7:200
The Board of Krebs Biochemicals has approved a Scheme of Amalgamation to merge with Ipca Laboratories Limited to achieve operational synergies and cost optimization. Under the proposed ratio, shareholders of Krebs will receive 7 equity shares of Ipca Laboratories for every 200 shares held in Krebs. Krebs reported a total income of Rs. 26 crore in FY26, which is significantly smaller than Ipca's Rs. 7,431 crore. The merger aims to integrate Krebs' specialized fermentation-based API manufacturing capabilities into Ipca's larger ecosystem, securing supply chains for key therapeutic ingredients.
Key Highlights
Share swap ratio of 7 fully paid-up equity shares of Ipca (Re. 1 each) for every 200 shares of Krebs (Rs. 10 each).
Ipca Laboratories reported a standalone total income of Rs. 7,431 crore for FY26 compared to Krebs' Rs. 26 crore.
The merger provides Ipca with fermentation-based API manufacturing facilities that it currently lacks.
The appointed date for the scheme is April 1, 2026, subject to regulatory and shareholder approvals.
Krebs is currently loss-making and unable to fund R&D, which the merger aims to resolve through Ipca's financial strength.
👀 What to Watch
Investors should evaluate the implied value of the merger based on the 7:200 swap ratio relative to current market prices. The merger is generally positive for Krebs shareholders as it provides an exit into a much larger, profitable, and diversified pharmaceutical entity.
Krebs Biochemicals FY26 Revenue Drops 45% to ₹23.7 Cr; Net Loss Narrows to ₹16.9 Cr
Krebs Biochemicals reported a sharp 45.2% decline in annual revenue to ₹23.73 crore for FY26, largely due to the continued closure of its Vizag manufacturing unit since February 2025. While the annual net loss narrowed to ₹16.93 crore from ₹26.94 crore in FY25, the company's financial health remains critical with a deeply negative net worth of ₹162.75 crore. Operations at the Vizag plant remain suspended following orders from the Andhra Pradesh Pollution Control Board, significantly impacting production capacity.
Key Highlights
Annual revenue from operations fell 45.2% YoY to ₹2,373.16 lacs from ₹4,331.19 lacs.
Net loss for the full year narrowed to ₹1,693.31 lacs compared to a loss of ₹2,693.93 lacs in the previous year.
The Vizag manufacturing unit remains closed since Feb 7, 2025, due to a Pollution Control Board order.
Net worth deteriorated further to negative ₹16,275.47 lacs as of March 31, 2026.
Finance costs rose to ₹708.59 lacs for FY26, up from ₹591.42 lacs in FY25, indicating increasing debt servicing pressure.
👀 What to Watch
Investors should exercise extreme caution due to the company's negative net worth and the ongoing regulatory suspension of its primary manufacturing facility. Avoid fresh positions until there is a clear roadmap for plant reopening and capital restructuring.
Krebs Biochemicals Q3 Loss Narrows to ₹3.13 Cr; Revenue Declines 36% YoY
Krebs Biochemicals reported a sharp 36.6% YoY decline in revenue from operations to ₹7.27 crore for the quarter ended December 31, 2025. Despite the revenue drop, the company narrowed its net loss to ₹3.13 crore from ₹7.74 crore in the previous year's corresponding quarter, largely due to a significant reduction in operating expenses. A major operational headwind persists as the Vizag manufacturing unit remains closed following a February 2025 order from the Andhra Pradesh Pollution Control Board. The company's financial position is critical, with a negative net worth of ₹160.83 crore and total borrowings exceeding ₹221 crore.
Key Highlights
Revenue from operations fell to ₹727.42 lacs in Q3 FY26 compared to ₹1,146.72 lacs in Q3 FY25.
Net loss for the quarter narrowed to ₹312.65 lacs from ₹773.89 lacs YoY.
Total expenses were reduced by approximately 46% YoY to ₹1,040.49 lacs.
The Vizag manufacturing unit remains shut down since February 7, 2025, due to regulatory orders.
Company reports a deeply negative net worth of ₹16,083.25 lacs as of December 31, 2025.
👀 What to Watch
Investors should remain highly cautious as the company faces severe financial distress with negative net worth and ongoing regulatory issues at its Vizag plant. The significant drop in revenue and high debt levels make this a high-risk situation despite the narrowing of quarterly losses.
